Ahead of accelerated approval withdrawal hearing, Covis asks FDA to omit study potentially linking Makena and cancer
It’s been almost 10 months since the FDA granted Covis Pharma a hearing to review its controversial preterm birth drug Makena, which won an accelerated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
